How does sildenafil (phosphodiesterase type 5 inhibitor) affect blood pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How Sildenafil Affects Blood Pressure

Sildenafil causes mild, transient decreases in blood pressure through systemic vasodilation, typically reducing systolic/diastolic pressure by approximately 8-10/5-9 mmHg, with effects peaking 1-2 hours after dosing. 1

Mechanism of Blood Pressure Reduction

  • Sildenafil inhibits phosphodiesterase type 5 (PDE-5), which increases cyclic GMP in vascular smooth muscle, causing vasodilation in both pulmonary and systemic circulation 1
  • The vasodilatory effect results in mild peripheral arterial-venous dilatation, leading to modest preload and afterload reductions 1, 2
  • Single oral doses of 100 mg in healthy volunteers produced mean maximum decreases of 8/5 mmHg in supine blood pressure 1
  • After chronic dosing of 80 mg three times daily to healthy volunteers, the largest mean decrease was 9.0/8.4 mmHg 1

Blood Pressure Effects in Different Patient Populations

In hypertensive patients: After chronic dosing of 80 mg three times daily, mean reductions were 9.4/9.1 mmHg 1

In pulmonary arterial hypertension (PAH) patients: Lesser reductions of approximately 2/2 mmHg were observed with the same dosing regimen 1

The blood pressure reduction is not dose-dependent within the therapeutic range (25-100 mg), as similar effects were noted across all doses 1

Critical Safety Considerations

Absolute Contraindication with Nitrates

  • Never combine sildenafil with nitrate medications due to profound, potentially life-threatening hypotension from synergistic vasodilation 3
  • The combination causes synergistic increases in cGMP levels at different points along the NO-cGMP pathway, resulting in excessive blood pressure drops 4
  • Avoid nitrates for at least 24 hours after sildenafil use 3

Other Blood Pressure-Related Contraindications

  • Avoid sildenafil in patients with resting hypotension (BP <90/50 mmHg) 3, 1
  • Avoid in patients with severe left ventricular outflow obstruction 3, 1
  • Avoid in patients with autonomic dysfunction 3, 1
  • Control uncontrolled hypertension (BP ≥180/110 mmHg) before prescribing sildenafil 3

Safety with Antihypertensive Medications

Sildenafil can be safely prescribed with most antihypertensive agents without significant adverse reactions 3

  • Diuretics can be used in combination without significant safety concerns 3
  • Angiotensin II receptor blockers (ARBs) can be combined without increased adverse events 3
  • Beta blockers, alpha blockers, ACE inhibitors, and calcium antagonists did not show increased adverse events in retrospective analyses 4
  • Monitor blood pressure when co-administering blood pressure lowering drugs with sildenafil 1

Common Vasodilation-Related Side Effects

  • Headache occurs in 16% of patients, related to vasodilation 3, 4
  • Flushing occurs in 10% of patients 3, 4
  • Dizziness occurs in 2% of patients 4
  • The incidence of hypotension, orthostatic hypotension, and syncope was <2% and similar to placebo 4

Clinical Implications

  • The blood pressure effects are transient, with maximum effects at 1-2 hours post-dose and no difference from placebo at 8 hours 1
  • Carefully consider underlying conditions that could be adversely affected by vasodilatory effects, including patients on antihypertensive therapy, fluid depletion, or with cardiovascular instability 1
  • In clinical trials of patients with ischemic heart disease, sildenafil did not increase serious cardiovascular events, myocardial infarction, or death compared to placebo 2, 5

References

Guideline

Sildenafil Use in Hypertensive Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Overall cardiovascular profile of sildenafil citrate.

The American journal of cardiology, 1999

Research

Cardiovascular risk and sildenafil.

The American journal of cardiology, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.